NCT04312997View on ClinicalTrials.gov

The Use of PUL-042 Inhalation Solution to Reduce the Severity of COVID-19 in Adults Positive for SARS-CoV-2 Infection

PHASE2CompletedINTERVENTIONAL
Enrollment

101

Participants

Timeline

Start Date

June 16, 2020

Primary Completion Date

July 2, 2021

Study Completion Date

July 2, 2021

Conditions
COVID-19
Interventions
DRUG

PUL-042 Inhalation Solution

20.3 µg Pam2 : 29.8 µg ODN/mL (50 µg PUL-042)

DRUG

Placebo

Sterile saline for inhalation

Trial Locations (11)

33134

Clinical Research of South Florida Alliance for Multispecialty Research, Coral Gables

33308

Invesclinic US LLC, Fort Lauderdale

33321

DBC Research Corp., Tamarac

33612

Affinity Clinical Research, LLC, Tampa

41017

St. Elizabeth Healthcare, Edgewood

74006

Ascension St. John, Bartlesville

74104

Ascension St. John, Tulsa

77030

MD Anderson Cancer Center, Houston

77057

Next Level Urgent Care, Houston

92404

Premeir Urgent Care of California, San Bernardino

92868

University of California Irvine, Orange

All Listed Sponsors
collaborator

United States Department of Defense

FED

lead

Pulmotect, Inc.

INDUSTRY

NCT04312997 - The Use of PUL-042 Inhalation Solution to Reduce the Severity of COVID-19 in Adults Positive for SARS-CoV-2 Infection | Biotech Hunter | Biotech Hunter